After Hours Summary: CBAY +47% after landing gout license deal; SHAK +5%, CC +2%, IDXX +0.5% higher on index change news... AGRX -72% on Twirla update, TSLA -2% after missing delivery targetsAfter Hours Gainers:
- CBAY +47.4% (Kowa Pharmaceuticals America announces agreement with CymaBay Therapeutics to license gout compound)
- SHAK +4.6% (to Join S&P SmallCap 600)
- KOPN +2.1% and DEPO +1.3%(continued strength)
- CC +1.5% (to join S&P MidCap 400)
- ATHN +0.8% (upgraded to Overweight at KeyBanc)
- AMGN +0.8% (favorable patent ruling news)
- IDXX +0.5% (to join the S&P 500)
After Hours Losers:
- AGRX -71.8% (announces top-line results from its Phase 3 SECURE clinical trial of Twirla; plans to resubmit its NDA for Twirla in the first half of 2017 on the basis of the SECURE results)
- ACUR -10.7% (announces they are exploring a full range of financing and strategic alternatives, including a possible sale of the company)
- TSLA -1.8% (Misses Q4 delivery targets on production delays related to new autopilot hardware; net orders set new record)
- REGN -1.6% (unfavorable patent ruling news)
- ARR -1% (announces January 2017 dividend rate per common share of $0.19 vs $0.22/share prior month)